LOXO-305
E566975
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton’s tyrosine kinase inhibitor
ⓘ
investigational drug ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ |
| actsOnCellType | B lymphocytes ⓘ |
| belongsToPortfolioOf | Eli Lilly oncology pipeline ⓘ |
| bindingType | non-covalent ⓘ |
| clinicalDevelopmentPhase | clinical trials ⓘ |
| designedTo |
overcome resistance to covalent BTK inhibitors
ⓘ
retain activity in patients with BTK C481 mutations ⓘ |
| developedFor |
B-cell malignancies
ⓘ
Waldenström macroglobulinemia ⓘ chronic lymphocytic leukemia ⓘ mantle cell lymphoma ⓘ other relapsed or refractory B-cell non-Hodgkin lymphomas ⓘ small lymphocytic lymphoma ⓘ |
| developer |
Eli Lilly and Company
NERFINISHED
ⓘ
Loxo Oncology NERFINISHED ⓘ |
| dosingSchedule | once-daily ⓘ |
| drugClass |
BTK inhibitor
ⓘ
tyrosine kinase inhibitor ⓘ |
| generation | non-covalent next-generation BTK inhibitor ⓘ |
| hasAdministrationForm | oral tablet ⓘ |
| hasAlternativeName |
LOXO 305
NERFINISHED
ⓘ
Loxo-305 NERFINISHED ⓘ pirtobrutinib NERFINISHED ⓘ |
| hasEffect |
inhibition of B-cell receptor signaling
ⓘ
reduction of malignant B-cell proliferation ⓘ |
| hasMechanismOfAction | BTK inhibition ⓘ |
| hasProperty |
high kinome selectivity
ⓘ
reversible BTK binding ⓘ |
| hasTarget | Bruton’s tyrosine kinase NERFINISHED ⓘ |
| intendedUse |
treatment of chronic lymphocytic leukemia after prior BTK inhibitor therapy
ⓘ
treatment of relapsed or refractory B-cell malignancies ⓘ |
| investigatedIn |
other B-cell non-Hodgkin lymphomas
ⓘ
relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ |
| molecularTargetType | non-receptor tyrosine kinase ⓘ |
| routeOfAdministration | oral ⓘ |
| selectivity | highly selective for BTK ⓘ |
| therapeuticArea |
hematologic malignancies
ⓘ
oncology ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology